Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | GRM5 | P41594 | 6/20 | 0.46 |
| ▸ | CLPP | Q16740 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22280528 | 0.92 | HDAC4 (0.53) | FAAHMGLLHDAC4HDAC6GPR119 | |
| SCHEMBL4414338 | 0.89 | GPR119 (0.56) | HDAC4HDAC6GPR119ALDH1A1SMN1; SMN2 | |
| SCHEMBL25401566 | 0.88 | ALDH1A1 (0.59) | FAAHMGLLALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22265342 | 0.84 | FAAH (0.50) | FAAHMGLLHDAC4HDAC6GRM5 | |
| SCHEMBL14752915 | 0.82 | GRM5 (0.48) | FAAHMGLLGPR119GRM5 | |
| SCHEMBL22265692 | 0.82 | SPHK2 (0.68) | FAAHMGLL | |
| SCHEMBL16933872 | 0.82 | SPHK2 (0.68) | FAAHMGLL | |
| SCHEMBL22265749 | 0.82 | SPHK2 (0.68) | FAAHMGLL | |
| SCHEMBL16934278 | 0.82 | SPHK2 (0.68) | FAAHMGLL | |
| SCHEMBL22280276 | 0.82 | LMNA (0.57) | HDAC4HDAC6GPR119GRM5CLPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-31 | — | — | US | disclosed |
| US-20220089581-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | disclosed |
| EP-3914592-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | University of Virginia Patent Foundation (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020154431-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | LYNCH KEVIN R (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020154431-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | LYNCH KEVIN R (US) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089581-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | FAAH 4190/4885MGLL 4803/4885HDAC4 2770/4885 |
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | SPNS2, SLC20A2, S1PR2 | FAAH 3735/4885MGLL 1829/4885HDAC4 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.